Why Regeneron Pharmaceuticals Dropped 11.3% in September
Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P Global Market Intelligence.
Regeneron and its partner Sanofi (NYSE: SNY) made a number of announcements during the month that captured the market's attention.
Here's an overview of the key developments from the month:
Source: Fool.com
Sanofi S.A. ADR Stock
€48.40
-1.630%
With 11 Buy predictions and not the single Sell prediction the community is currently very high on Sanofi S.A. ADR.
As a result the target price of 55 € shows a slightly positive potential of 13.64% compared to the current price of 48.4 € for Sanofi S.A. ADR.
